Agenus (Formerly known as Antigenics Inc. - New York) (AGEN)’ Prophage Vaccine For Glioma Hailed As A "Very Promising Therapy" In An Editorial Published In The Journal Neuro-Oncology
1/21/2014 9:11:33 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme (GBM) were hailed as ‘exciting’ and a ‘very promising therapy’ in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by